Treatment of Neurological Diseases—Current and Emerging Applications

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Neurology".

Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 2011

Special Issue Editor


E-Mail Website
Guest Editor
Department of Senior Exercise Prescription, Gwangju Health University, 73, Bungmun-daero 419beon-gil, Gwangju 62287, Republic of Korea
Interests: pain science; musculoskeletal disorders; neuroscience
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, entitled "Treatment of Neurological Diseases—Current and Emerging Applications", focuses on the rapidly evolving field of neurology, which is currently witnessing groundbreaking advancements in both the understanding and treatment of neurological disorders. This Special Issue aims to provide a comprehensive overview of the latest therapeutic approaches and emerging technologies being applied to combat a range of neurological diseases such as Alzheimer’s, Parkinson’s, stroke, multiple sclerosis, and epilepsy, among others.

In recent years, significant progress has been made in understanding the pathophysiology of these disorders, leading to the development of novel treatment strategies. These include precision medicine approaches, gene and cell therapies, advanced neuroimaging techniques, and neuromodulation devices. Furthermore, the integration of artificial intelligence and machine learning into diagnostics and treatment monitoring is opening new avenues for personalized care and real-time decision-making in neurological treatment.

This Special Issue aims to collate leading researchers and clinicians to present state-of-the-art research, clinical trials, and reviews on both well-established and experimental therapies. It will cover the entire spectrum from pharmacological treatments to innovative non-invasive techniques, including the use of neuroprotective agents, immunotherapies, and rehabilitation approaches.

Through this collection, we aim to foster a deeper understanding of both the current state and the future potential of neurological disease treatment, providing valuable insights for healthcare professionals, researchers, and policymakers. This Special Issue also emphasizes the importance of translating research findings into clinical practice to improve patient outcomes in the field of neurology.

Dr. Hyunjoong Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurological diseases
  • neurodegenerative diseases
  • neuroprotection
  • gene therapy
  • cell therapy
  • neuroimaging
  • neuromodulation
  • precision medicine
  • artificial intelligence
  • rehabilitation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 3543 KiB  
Article
Rosiridin Protects Against Aluminum Chloride-Induced Memory Impairment via Modulation of BDNF/NFκB/PI3K/Akt Pathway in Rats
by Sana Saeed Alqarni, Muhammad Afzal, Khalid Saad Alharbi, Sattam Khulaif Alenezi, Tariq G. Alsahli, Shafqat Zaidi, Ahmed Essam Altyar, Nehmat Ghaboura, Imran Kazmi, Mohammad Jaffar Sadiq Mantargi and Faisal Imam
Medicina 2024, 60(11), 1812; https://doi.org/10.3390/medicina60111812 - 4 Nov 2024
Viewed by 1580
Abstract
Background and Objectives: Rosiridin is a monoterpene with outstanding monoamine inhibitory activity that is useful to treat depressive episodes and rapid-onset dementia. The current investigation aims to evaluate the neurologically protective impact of rosiridin, which opposes aluminum chloride (AlCl3) and causes [...] Read more.
Background and Objectives: Rosiridin is a monoterpene with outstanding monoamine inhibitory activity that is useful to treat depressive episodes and rapid-onset dementia. The current investigation aims to evaluate the neurologically protective impact of rosiridin, which opposes aluminum chloride (AlCl3) and causes memory dysfunction in rats. Materials and Methods: Memory impairment was developed in Wistar rats by administering AlCl3 (100 mg/kg p.o.) orally for 42 days and then supplemented with rosiridin at 10 and 20 mg/kg/p.o. Upon completion of the investigation, the behavior factor was performed utilizing the Y-maze, Morris Water Maze, and open field tests. Estimating numerous biological factors, such as nitric oxide (NO), oxidative stress (malondialdehyde MDA), acetylcholinesterase (AChE), butyrylcholinesterase levels (BuChE), antioxidants (glutathione GSH, catalase CAT, and superoxide dismutases SODs) and neurotransmitter (serotonin-5HT, dopamine-DA, acetylcholine-Ach) in the brain. Furthermore, interleukin-6 (IL-6), IL-1β, tumor necrosis factor (TNF-α), brain-derived neurotrophic factor (BNDF), nuclear factor kappa B (NFᴋB), phosphatidylinositol 3-kinase (PI3K), and pAkt were assessed in the diffused brain cells. Results: The rosiridin-treated group significantly improved in terms of behavioral parameters, including in the Y-maze, Morris Water Maze, and open field tests. Further, rosiridin restored biochemical parameters, including NO, oxidative stress AChE, BuChE, antioxidants, neurotransmitters, IL-6, IL-1β, TNF-α, BNDF, NFᴋB, PI3K, and pAkt compared to AlCl3. Conclusions: The current investigation reveals that rosiridin could ameliorate the impairment of memory that AlCl3 causes in rats via improvements in behavioral and restored biochemical parameters. Full article
Show Figures

Figure 1

Back to TopTop